RESILIENCE-R-2023
Aim
• OB1) Design early and high-throughput diagnosis (point of care as well as reach-back capabilities) of acute and late radiation-induced human health effects in preparedness of RN event
• OB2) Design of innovative decorporating and human decontaminating agents for NR threats
• OB3) Elaborate phage-based diagnostics and therapeutics for infections caused by CBRN relevant bacteria
• OB4) Design new generation vaccines against Monkeypox virus (MPXV) and Variola virus (VARV)
• OB5) Design next generation of re-activators of cholinesterases against nerve agent intoxication.
Description
Current lab-scale MCMs will be brought to TRL4/5 through further optimisation and testing. A panel of complementary activities will be undertaken, including knowledge generation (new biomarkers of late radiation induced effects, new concepts of vaccines), knowledge integration (new vaccines, phage therapies and decorporating agents, new in vitro diagnostic tools for rapid and on-field identification of microorganisms, evaluation of new reactivators of cholinesterases against nerve agent intoxication), and studies (in vitro and in vivo assays for preclinical proof of concept studies of MCM candidates, characterisation of drugs and devices for further formulation and vectorisation).
Lead Partner
Commissariat à l'énergie atomique et aux énergies alternatives (France)
Project Partners
- Agencia Estatal Consejo Superior de Investigaciones Científicas (Spain)
- IST-ID Associação do Instituto Superior Técnico para a Investigação e o Desenvolvimento (Portugal)
- AIT Austrian Institute of Technology GmbH (Austria)
- Bundesinstitut für Risikobewertung (Germany)
- Bundesamt für Strahlenschutz (Germany)
- Centre national de la recherche scientifique (France)
- European Research Infrastructure on Highly Pathogenic Agents (Belgium)
- École Royale Militaire - Koninklijke Militaire School (Belgium)
- Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. (Germany)
- Helsingin yliopisto (Finland)
- Institut de Radioprotection et de sûreté nucléaire (France)
- Institut für Mikrobiologie der Bundeswehr (Germany)
- Bundesministerium der Verteidigung (Germany)
- Institut für Pharmakologie und Toxikologie der Bundeswehr (Germany)
- Institut für Radiobiologie der Bundeswehr (Germany)
- Institut National de la Santé et de la Recherche Médicale (France)
- Institut Pasteur (France)
- Institut za medicinska istraživanja i medicinu rada (Croatia)
- Invitris (Germany)
- Jafral, Biotehnološke raziskave in razvoj, d.o.o. (Slovenia)
- Johann Wolfgang Goethe-Universität Frankfurt am Main (Germany)
- Katholieke Universiteit Leuven (Belgium)
- Latvijas Universitāte (Latvia)
- MB Pharma s.r.o. (Czech Republic)
- Microfluidic ChipShop GmbH (Germany)
- Ministère des Armées (France)
- Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Onderzoek (TNO) (Netherlands)
- Nemzeti Népegészségügyi és Gyógyszerészeti Központ (Hungary)
- OPGS Pharmaceuticals (France)
- Rīga Stradiņš University (Latvia)
- Totalförsvarets forskningsinstitut (Sweden)
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz (Germany)
- Universitat Autònoma de Barcelona (Spain)
- Université d'Orléans (France), Université de Rouen Normandie (France)
- Université Paris Cité (France)
- Universiteit Gent (Belgium)
- Univerzita Hradec Králové (Czech Republic)
- Univerzita obrany (Czech Republic)
- Uniwersytet Gdański (Poland)
- Uniwersytet Wrocławski (Poland)
- Valneva (France)
- Valneva Austria GmbH (Austria)
Views and opinions expressed are those of the author(s) and do not necessarily reflect those of the European Union or the European Defence Fund. Neither the European Union nor the granting authority can be held responsible for them.
